

*The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.*

## **Instruction for the Nomination Committee of EQL Pharma AB**

The Nomination Committee of EQL Pharma AB, Reg. No. 556713-3425 (the “**Company**”), proposes that an instruction for the Nomination Committee shall be adopted in accordance with the following substantial terms.

The Chairman of the board of directors shall, as soon as possible after the registered ownership in the Company as of 31 December 2022 is known, contact the three largest registered owners in terms of votes according to the Company's share register, and ask them to appoint one member each to the Nomination Committee. If such shareholders do not wish to appoint a member, the following largest registered owners in terms of votes shall be asked in order of size, until three owner representatives have been appointed. The appointed members shall comprise the Nomination Committee. The Chairman of the board of directors shall convene but not be a part of the Nomination Committee as a member, but the Nomination Committee may choose to co-opt the Chairman of the board of directors to a part of the work carried out by the Nomination Committee. The Nomination Committee shall then appoint a chairman among its members. The names of the members of the Nomination Committee shall be published by the Company no later than six months before the annual general meeting in 2023.

If a shareholder who has appointed a member to the Nomination Committee, before the Nomination Committee's assignment has been completed, receives a lower placement on the list of held votes in the Company, the member appointed by the shareholder shall, if the Nomination Committee so decides, be replaced by a new member appointed by the registered shareholder who at the time holds the largest amount of votes and is not already a member of the Nomination committee. Should any of the members of the Nomination Committee, before the Nomination Committee's assignment has been completed, resign for any other reason or cease to represent the shareholder who appointed the member, such member shall, if the one who appointed the member so requests, be replaced by a new member appointed by the shareholder.

The term of office for the appointed Nomination Committee shall run until a new Nomination Committee has taken office. No remuneration for the members' work in the Nomination Committee shall be paid. If necessary, the Company shall be able to bear reasonable costs that the Nomination Committee deems necessary for it to be able to fulfill its assignment. The Nomination Committee may also co-opt members to the Nomination Committee if deemed appropriate; a co-opted member shall not, however, have the right to vote in the Nomination Committee.

---

July 2022

The Nomination Committee of EQL Pharma AB (publ)